This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med 1999; 341: 1165–1173.
Oberlin O, Rey A, Desfachelles AS, Philip T, Plantaz D, Schmitt C et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic ewing tumors: a study by the Société Française des Cancers de l’Enfant. J Clin Oncol 2006; 24: 3997–4002.
Hartmann O, Valteau-Couanet D, Vassal G, Lapierre V, Brugières L, Delgado R et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 1999; 23: 789–795.
Ladenstein RL, Poetschger U, Luksch R, Brock P, Castel V, Yaniv I et al. Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: results from the HR-NBL1/SIOPEN trial. J Clin Oncol 2011; 29: 2011 (suppl; abstract 2).
Ladenstein RL, Poetschger U, Luksch R, Brock P, Castel V, Yaniv I . Final results from the HR-NBL1/SIOPEN Trial favour Busulphan-Melphalan as Superior Myeloablative Therapy (MAT) for high risk neuroblastoma. Abstract ANR 2012: Advances in Neuroblastoma Research; Toronto, Ontario, Canada, 2012.
Ladenstein R, Pötschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O et al. Primary disseminated multifocal ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol 2010; 28: 3284–3291.
Slattery JT, Kalhorn TF, McDonald GB, Lambert K, Buckner CD, Bensinger WI et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 1996; 14: 1484–1494.
Cantoni N, Gerull S, Heim D, Halter J, Bucher C, Buser A et al. Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT. Bone Marrow Transplant 2011; 46: 344–349.
Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant 2010; 16: 157–168.
Hassan Z, Hellström-Lindberg E, Alsadi S, Edgren M, Hägglund H, Hassan M . The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo. Bone Marrow Transplant 2002; 30: 141–147.
Hassan M, Ljungman P, Ringdén O, Hassan Z, Oberg G, Nilsson C et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000; 25: 915–924.
Nilsson C, Forsman J, Hassan Z, Abedi-Valugerdi M, O’Connor C, Concha H et al. Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice. Exp Hematol 2005; 33: 380–387.
Sadeghi B, Jansson M, Hassan Z, Mints M, Hägglund H, Abedi-Valugerdi M et al. The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model. Bone Marrow Transplant 2008; 41: 895–904.
Kerbauy FR, Tirapelli B, Akabane H, Oliveira JSR . The effect of administration order of BU and CY on toxicity in hematopoietic SCT in humans. Bone Marrow Transplant 2009; 43: 883–885.
Bouligand J, Boland I, Valteau-Couanet D, Deroussent A, Kalifa C, Hartmann O et al. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). Bone Marrow Transplant 2003; 32: 979–986.
Acknowledgements
We are grateful to Lorna Saint Ange for editing. We thank Pierre Fabre Medicament who provided financial research support for the current study but did not participate in the conduct of the study or data analyses.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Dourthe, M., Ternès, N., Gajda, D. et al. Busulfan–Melphalan followed by autologous stem cell transplantation in patients with high-risk neuroblastoma or Ewing sarcoma: an exposed–unexposed study evaluating the clinical impact of the order of drug administration. Bone Marrow Transplant 51, 1265–1267 (2016). https://doi.org/10.1038/bmt.2016.109
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.109
This article is cited by
-
Veno-occlusive disease after high-dose busulfan–melphalan in neuroblastoma
Bone Marrow Transplantation (2020)
-
Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma
Bone Marrow Transplantation (2018)